MRK

NYSE · Pharmaceuticals

Merck & Co. Inc.

S&P 500 Dow Jones Mega-Cap Stocks Blue Chip Stocks Pharmaceutical Stocks Healthcare Stocks Best Dividend Stocks Highest Dividend Yield

$111.38

-0.92 (-0.82%)

As of May 8, 9:30 PM ET ·

Financial Highlights (FY 2026)

Revenue

64.60B

Net Income

18.14B

Gross Margin

77.1%

Profit Margin

28.1%

Rev Growth

+3.1%

D/E Ratio

0.94

Revenue & Net Income

Margin Trends

	FY 2026	FY 2025	FY 2024	FY 2023
Gross Margin	77.1%	77.1%	60.0%	60.0%
Operating Margin	32.6%	29.4%	19.9%	18.6%
Profit Margin	28.1%	26.7%	14.5%	15.3%

Income Statement

	FY 2026	FY 2025	FY 2024	FY 2023
Revenue	64.60B	62.65B	122.92B	97.21B
Gross Profit	49.80B	48.29B	73.70B	58.29B
Operating Income	21.09B	18.40B	24.40B	18.09B
Net Income	18.14B	15.83B	17.77B	14.84B
Gross Margin	77.1%	77.1%	60.0%	60.0%
Operating Margin	32.6%	29.4%	19.9%	18.6%
Profit Margin	28.1%	26.7%	14.5%	15.3%
Rev Growth	+3.1%	+3.1%	+3.7%	+0.8%

Balance Sheet

	FY 2026	FY 2025	FY 2024	FY 2023
Total Debt	67.62B	67.62B	126.52B	165.60B
Total Equity	72.09B	72.09B	163.18B	146.99B
D/E Ratio	0.94	0.94	0.78	1.13

Cash Flow

	FY 2026	FY 2025	FY 2024	FY 2023
EBITDA	24.92B	22.96B	40.31B	27.40B
Free Cash Flow	—	—	15.03B	9.18B